BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $338,308 | -16.5% | 4,970 | +0.1% | 0.01% | -18.2% |
| Q2 2023 | $405,375 | +10.5% | 4,966 | +0.4% | 0.01% | +10.0% |
| Q1 2023 | $366,870 | -10.0% | 4,945 | +0.5% | 0.01% | -9.1% |
| Q4 2022 | $407,770 | -1.5% | 4,920 | +237.7% | 0.01% | 0.0% |
| Q3 2022 | $414,000 | -23.9% | 1,457 | -7.1% | 0.01% | -15.4% |
| Q2 2022 | $544,000 | -19.6% | 1,568 | +0.3% | 0.01% | -13.3% |
| Q1 2022 | $677,000 | -26.0% | 1,563 | -11.6% | 0.02% | -16.7% |
| Q4 2021 | $915,000 | +6.9% | 1,768 | +0.1% | 0.02% | +5.9% |
| Q3 2021 | $856,000 | -70.6% | 1,766 | -72.7% | 0.02% | -66.7% |
| Q2 2021 | $2,916,000 | +18.0% | 6,477 | +0.1% | 0.05% | +15.9% |
| Q1 2021 | $2,472,000 | -41.4% | 6,472 | -51.2% | 0.04% | -21.4% |
| Q4 2020 | $4,215,000 | +20.0% | 13,275 | -0.2% | 0.06% | +14.3% |
| Q3 2020 | $3,512,000 | 0.0% | 13,300 | 0.0% | 0.05% | 0.0% |
| Q2 2020 | $3,512,000 | +39.9% | 13,300 | +0.5% | 0.05% | +28.9% |
| Q1 2020 | $2,510,000 | +5.1% | 13,239 | +21.6% | 0.04% | -11.6% |
| Q4 2019 | $2,389,000 | +12.5% | 10,885 | +0.3% | 0.04% | -8.5% |
| Q3 2019 | $2,124,000 | -5.7% | 10,853 | +0.5% | 0.05% | -11.3% |
| Q2 2019 | $2,252,000 | +68.8% | 10,801 | +60.8% | 0.05% | +120.8% |
| Q1 2019 | $1,334,000 | +29.1% | 6,719 | -5.9% | 0.02% | +41.2% |
| Q4 2018 | $1,033,000 | -28.9% | 7,139 | +0.4% | 0.02% | -22.7% |
| Q3 2018 | $1,452,000 | +32.8% | 7,112 | -3.7% | 0.02% | +37.5% |
| Q2 2018 | $1,093,000 | -5.6% | 7,385 | -3.7% | 0.02% | -15.8% |
| Q1 2018 | $1,158,000 | +82.1% | 7,668 | +56.3% | 0.02% | +72.7% |
| Q4 2017 | $636,000 | +7.8% | 4,906 | +0.5% | 0.01% | +10.0% |
| Q3 2017 | $590,000 | -21.9% | 4,884 | -24.0% | 0.01% | -23.1% |
| Q2 2017 | $755,000 | +15.4% | 6,426 | -0.1% | 0.01% | +8.3% |
| Q1 2017 | $654,000 | -1.1% | 6,430 | 0.0% | 0.01% | -7.7% |
| Q4 2016 | $661,000 | -6.0% | 6,430 | +0.1% | 0.01% | -13.3% |
| Q3 2016 | $703,000 | -2.9% | 6,422 | +0.1% | 0.02% | 0.0% |
| Q2 2016 | $724,000 | +19.5% | 6,416 | 0.0% | 0.02% | +15.4% |
| Q1 2016 | $606,000 | +271.8% | 6,416 | +254.5% | 0.01% | +333.3% |
| Q4 2015 | $163,000 | -2.4% | 1,810 | 0.0% | 0.00% | -25.0% |
| Q3 2015 | $167,000 | -6.2% | 1,810 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $178,000 | -11.0% | 1,810 | -9.0% | 0.00% | 0.0% |
| Q1 2015 | $200,000 | – | 1,990 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |